



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

SIOPEN BIOPORTAL

SIOPEN (the European neuroblastoma research group) in Austria is responsible for the international implementation of the study (sponsor). The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor's representative).

Background

Neuroblastoma and ganglioneuroblastoma are malignant tumours of the nervous system. They are among the most common forms of cancer in children and adolescents, and generally affect children under six years of age. The course of the disease varies widely: some cases are very aggressive, while other tumours are less malignant and regress spontaneously. As a result, the chances of recovery also vary significantly. Each year, 15-20 children and adolescents in Switzerland are affected by this disease and can take part in the study.

Why does the study need to be done?

The study aims to collect data on the diagnosis, treatment and effects of these diseases from patients in 29 different countries in order to generate new scientific findings. This work should result in a greater understanding of why these diseases develop and how their treatment can be improved in the future. In addition, the patients' samples are to be stored in a virtual biobank for future research purposes.

Contact details for the sponsor's representative in Switzerland:

SPOG Coordinating Center

Partner Relations

Effingerstrasse 33

3008 Bern

E-mail: partnerrelations@spog.ch

Phone: +41 31 389 91 89